Delisting riskPopularity #5,132
INTS · NASDAQ · Biotechnology

Intensity Therapeutics (INTS)

Develops INT230-6, a tumor-injection treatment candidate for solid cancers.

$4.06
vs last close+0.04 (+1.12%)
  1. Intensity (INTS) Q2 Net Loss Drops 50%

    The Motley Fool